Alaunos announces preclinical ALN1003 data; cash only $0.354M, runway into Q2 2026

Alaunos Therapeutics, Inc.

ALN1003 showed significantly lower HOMA-IR (p=0.0006) and higher adiponectin-to-leptin ratio in DIO mouse models.
Blinded liver histology: ALN1003-treated mice had mean NAS scores of 2.7 and 1.3 vs control score of 5.
Data are from non-GLP studies with small sample sizes; no human trials conducted yet.
Cash and equivalents $0.354M as of March 31, 2026; company seeking additional financing.
Plans to advance ALN1003 with further preclinical dose optimization and metabolic phenotyping.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.